Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

Annals of surgical oncology - 1 Apr 2014

Wang Xiang, Chen Jin-Xiu, Liu Jin-Ping, You Chao, Liu Yan-Hui, Mao Qing

Abstract excerpt

PURPOSE: Our aim was to investigate the relationship between mutant p53 and the prognosis of malignant glioma treated with temozolomide, and the regulation of mutant TP53 induced drug resistance, by molecular experimentation and a clinical trial. METHODS: Adult patients with newly surgical diagnosed glioblastoma were randomly assigned to receive either temozolomide or semustine after radiation treatment. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to RNA, Small Interfering

Share to Survival Rate

Share to Temozolomide

Source

Identifiers

PMID: 24248532
DOI: 10.1245/s10434-013-3380-0

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.PMID 24248532Read ↗

Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.Semantic proximity Read ↗

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.Semantic proximity Read ↗

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.Semantic proximity Read ↗

Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.Semantic proximity Read ↗

TP53 mutations and survival in patients with histologically defined Glioblastoma, IDH-wildtype.Semantic proximity Read ↗

MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 AxisSemantic proximity Read ↗

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.Semantic proximity Read ↗

p53 and brain tumors: from gene mutations to gene therapy.Semantic proximity Read ↗

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastomaSemantic proximity Read ↗

Blood-tissue analysis of TP53 polymorphisms and survival of patients with glioma.Semantic proximity Read ↗

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.Semantic proximity Read ↗

MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.